NCT01469884 - Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Renal AllograftHepatitis C

Interventions

DRUG

Everolimus

The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.

DRUG

Cyclosporine

Trough level should be between 100 and 200ng/ml.

DRUG

Tacrolimus

Trough level should be between 5 and 10ng/ml.

Trial Locations (1)

90020090

Irmandade Da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre